ReviewA new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
Introduction
Gemifloxacin is a novel fluorinated, naphthyridone antibacterial agent which retains the excellent activity against Gram-negative pathogens associated with most members of the fluoroquinolone class whilst possessing enhanced potency against Gram-positive bacterial pathogens, notably Streptococcus pneumoniae, exceeding that of other third generation agents [1], [2].
The overall safety profile of the quinolones compares favourably with other antibacterial classes [3] although severe low frequency adverse drug reactions (ADRs) have occurred with a small number of specific quinolones. These have included temafloxacin haemolytic-uraemic syndrome [4], hepatotoxicity caused by trovafloxacin [3], [5], [6] and nephritis and skin reactions caused by tosufloxacin [3]. These agents have exclusively in common the 1 [2], [4] difluorophenyl side chain and such reactions probably do have, at least in part, an immune basis [7]. Severe phototoxicity is known to relate to side chain poly-fluorination and especially to compounds, such as Bay 3118 and clinafloxacin, with 8-chloro substitutions [3], [8], [9]. None of these structural properties applies to gemifloxacin.
Minor class ADRs, affecting the entire group and differing in frequency among class members, include those affecting the CNS, gastro-intestinal tract and skin [3], [8], [10]. Recently, a further class effect, prolongation of the rate corrected QT (QTc) interval (averaging 3–6 ms) similar to that with macrolides, has been recognised [11]. This has, exceptionally, been associated with cardiac arrhythmias in predisposed patients [7], [11], [12], [13], [14].
This review assesses the safety profile of gemifloxacin 320 mg (equivalent to 400 mg mesylate salt) in the context of the known class effects of both the second-generation quinolone antibacterials (ciprofloxacin and levofloxacin) and the more potent third generation congeners, notably the 8-methoxy sub-class—moxifloxacin and gatifloxacin. The safety profile of oral gemifloxacin and comparators is based on clinical trials involving 6775 patients receiving 320 mg gemifloxacin. In addition, results are presented from safety studies in healthy volunteers and special populations. The lack of those serious adverse events (AEs), which have recently been associated with other quinolone agents [3], [7], [11] is highlighted.
Section snippets
Materials and methods
The indications studied in the clinical trials comprised: acute exacerbations of chronic bronchitis (AECB) [9 trials], community-acquired pneumonia (CAP) [4 trials], urinary tract infection (UTI) [4 trials], acute bacterial sinusitis (ABS) [4 trials], skin and skin structure infections [1 trial] and non-gonococcal urethritis [1 trial]. The dose of oral gemifloxacin received was 320 mg once daily for between 5 and 14 days. Comparators, which included oral ciprofloxacin, ofloxacin, levofloxacin,
Demography and exposure
The clinical studies included 12,023 patients, of whom 6775 received oral gemifloxacin 320 mg once daily and 5248 received a comparator. All patients received at least one dose of study medication and were well matched with respect to demographic characteristics (Table 1). The most frequent actual durations of exposure to gemifloxacin were 4–5 days (3009 patients: 44.4% of 6775 total), 6–7 days (1911: 28.2%) and 8–10 days (812: 12.0%): 1903 (36.3%) patients received various comparators for 6–7
Discussion
The evolution of the quinolones during the 1990s has led to increasingly broad-spectrum compounds with markedly enhanced potency against Gram-positive pathogens. However, this has not been without molecular casualties [24] and a number of agents have been withdrawn or abandoned. This has resulted from haemolytic-uraemic syndrome (temafloxacin [4]), severe hepatic reactions (trovafloxacin [3], [25]), nephritis, dermatological and haematological reactions (tosulfoxacin [11]), severe phototoxicity
References (27)
- et al.
Anti-streptococcal activity of SB−265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines
Diagn Microbiol Infect Dis
(1999) New antibiotics for community acquired lower respiratory tract infections: improved activity at a cost?
Int J Antimicrob Agents
(2000)- et al.
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
Antimicrob Agents Chemother
(1997) - et al.
Comparative tolerability of the newer fluoroquinolone antibacterials
Drug Saf
(1999) - et al.
Temafloxacin syndrome: review of 95 cases
Clin Infect Dis
(1994) - EMEA (European Agency for the Evaluation of Medicinal Products). Public statement on Trovan/Trovan IV/Turvel/Turvel IV...
- FDA (Food and Drug Administration, US Department of Health and Human Services). FDA Talk Paper: FDA issues public...
- et al.
Tolerability of fluoroquinolone antibiotics: past, present and future
Drug Saf
(1995) Structure-activity and structure-side-effect relationships for the fluoroquinolone antibacterials
J Antimicrob Chemother
(1994)- et al.
Fluoroquinolone toxicity profiles: a review focusing on newer agents
Clin Infect Dis
(1999)
Quinolone induced QT interval prolongation: a not so unexpected class effect
J Antimicrob Chemother
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin
Pharmacotherpy
Authors reply [to correspondence]
Pharmacotherapy
Cited by (53)
Drug Allergy Practice Parameter Updates to Incorporate Into Your Clinical Practice
2023, Journal of Allergy and Clinical Immunology: In PracticeAntibiotics in the management of tuberculosis and cancer
2023, Antibiotics - Therapeutic Spectrum and LimitationsDrug allergy: A 2022 practice parameter update
2022, Journal of Allergy and Clinical ImmunologyCitation Excerpt :These rashes occur in 2%-3% of patients treated, although the rate varies among different agents and appears to be highest for gemifloxacin.351-353 Allergic cross-reactivity among fluoroquinolones for delayed cutaneous rashes appears to be low; only 10% of patients who developed uncomplicated MDE on gemifloxacin reacted to ciprofloxacin (which was given immediately after the gemifloxacin course).353 PT is not useful in evaluation of delayed maculopapular exanthems.354
US FDA-Approved Antibiotics During the 21st Century
2022, Encyclopedia of Infection and ImmunityAntimicrobial agents and torsades de pointes
2022, Torsades de PointesGemifloxacin-Induced Allergic Myocardial Infarction: A Case Report
2019, Journal of Emergency MedicineCitation Excerpt :Serious cardiovascular events associated with gemifloxacin use have not been reported previously. A slight prolongation in QT interval (2.56 ms) was reported in gemifloxacin-treated patients without any cardiac dysrhythmias (2). Allergic myocardial infarction, known as Kounis syndrome, is characterized by the concurrence of acute coronary syndrome with mast cell activation induced by inflammatory mediators released during allergic reaction (3).